View:
SCHEDULE 13G
Amendment No. 0
ULTRAGENYX PHARMA INC
COMMON STOCK
Cusip #90400D108
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
Cusip #90400D108
Item 1: Reporting Person - FIL Limited
Item 2: (a) [ ]
(b) [ ]
Item 4: Bermuda
Item 5: 1,654,028
Item 6: 0
Item 7: 1,654,028
Item 8: 0
Item 9: 1,654,028
Item 11: 5.224%
Item 12: FI
Cusip #90400D108
Item 1: Reporting Person - Pandanus Partners, L.P.
Item 2: (a) [ ]
(b) [ ]
Item 4: Delaware
Item 5: 0
Item 6: 0
Item 7: 1,654,028
Item 8: 0
Item 9: 1,654,028
Item 11: 5.224%
Item 12: PN
Cusip #90400D108
Item 1: Reporting Person - Pandanus Associates, Inc.
Item 2: (a) [ ]
(b) [ ]
Item 4: Delaware
Item 5: 0
Item 6: 0
Item 7: 1,654,028
Item 8: 0
Item 9: 1,654,028
Item 11: 5.224%
Item 12: CO
Item 1(a). Name of Issuer:
ULTRAGENYX PHARMA INC
Item 1(b). Address of Issuer's Principal Executive Offices:
60 LEVERONI COURT
Novato, CA 94949
USA
Item 2(a). Name of Person Filing:
FIL Limited
Item 2(b). Address or Principal Business Office or, if None,
Residence:
Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda,
HM19
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
COMMON STOCK
Item 2(e). CUSIP Number:
90400D108
Item 3. Not Applicable
Item 4. Ownership
(a) Amount Beneficially Owned: 1,654,028
(b) Percent of Class: 5.224%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
1,654,028
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 1,654,028
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
See attached Exhibit A.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect. By signing below I certify that, to the best of my knowledge and
belief, the foreign regulatory scheme applicable to FIL Limited and its
various non-U.S. investment management subsidiaries included on this
Schedule 13G is substantially comparable to the regulatory scheme
applicable to the functionally equivalent U.S. institutions. I also
undertake to furnish to the Commission staff, upon request, information
that would otherwise be disclosed in a Schedule 13D.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
August 8, 2014
Date
/s/ Scott C. Goebel
Signature
Scott C. Goebel
Duly authorized under Power of Attorney effective as of May 5, 2014, by
and on behalf of FIL Limited and its direct and indirect subsidiaries*
* This power of attorney is incorporated herein by reference to
Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession
number: 0000318989-14-000096.
Exhibit A
Pursuant to the instructions in Item 7 of Schedule 13G,
the following table lists the identity and Item 3 classification, if
applicable, of each relevant entity that beneficially owns shares of the
security class being reported on this Schedule 13G.
Entity ITEM 3 Classification
FIL INVESTMENTS INTERNATIONAL FI
Pandanus Partners, L.P. ("Pandanus") owns shares of FIL
Limited ("FIL") voting stock. While the percentage of total voting power
represented by these shares of FIL voting stock may fluctuate as a result
of changes in the total number of shares of FIL voting stock outstanding
from time to time, it normally represents more than 25% and less than 50%
of the total votes which may be cast by all holders of FIL voting stock.
Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus.
Pandanus is owned by trusts for the benefit of members of the family of
Edward C. Johnson 3d but disclaims that any such member is a beneficial
owner of the securities reported on this Schedule 13G.
This filing reflects the securities beneficially owned, or
that may be deemed to be beneficially owned, by FIL, certain of its
subsidiaries and affiliates, and other companies (collectively, the "FIL
Reporters"). This filing does not reflect securities, if any, beneficially
owned by certain other companies whose beneficial ownership of securities
is disaggregated from that of the FIL Reporters in accordance with
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).
RULE 13d-1(k)(1) AGREEMENT
The undersigned persons, on August 8, 2014, agree and
consent to the joint filing on their behalf of this Schedule 13G in
connection with their beneficial ownership of the COMMON STOCK of
ULTRAGENYX PHARMA INC at August 6, 2014.
FIL Limited
By /s/ Scott C. Goebel
Scott C. Goebel
Duly authorized under Power of Attorney effective as of May 5, 2014, by
and on behalf of FIL Limited and its direct and indirect subsidiaries*
Pandanus Partners, L.P
By /s/ Scott C. Goebel
Scott C. Goebel
Duly authorized under Power of Attorney effective as of May 2, 2014, by
Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.*
Pandanus Associates, Inc.
By /s/ Scott C. Goebel
Scott C. Goebel
Duly authorized under Power of Attorney effective as of May 2, 2014, by
and on behalf of Pandanus Associates, Inc.*
* This power of attorney is incorporated herein by reference to
Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession
number: 0000318989-14-000096.